This study has some limitations. First, biological factors such as GLUT-3, vascular endothelial growth factor, and hypoxia-inducible factor were not investigated. Recently, these biological factors were reported to be associated with 18F-FDG uptake in some malignant tumors 35. Vascular endothelial growth factor and hypoxia-inducible factor are upper reaches of the transduction pathway involving GLUT-1 in malignant tumors 36. As GLUT-1 has been used extensively to investigate the relationship between GLUT and 18F-FDG uptake in cancers, and Ki-67 has been frequently used to investigate the 18F-FDG uptake and cell proliferation, our study investigated relations of SUVmax with GLUT-1 and Ki-67. Second, breast cancers and gastrointestinal cancers such as colon cancer and gastric cancer were not included in this study. We could not include patients with these types of cancer because of the small number of patients who had undergone PET examinations and/or because of problems with pathological specimens. One reason for selecting NSCLC, PTC, and ESCC patients was that relatively larger numbers of patients in these categories had undergone both PET examinations and surgery at our institution. Differences in clinicopathological factors affecting SUVmax in a wider range of cancers should be investigated in the future.
There are no conflicts of interest.
1. Wahl RL, Jacene H, Kasamon Y, Lodge MA.From RECIST to PERESIT: Evolving considerations for PET response criteria in solid tumors.J Nucl Med2009;50:122S–150S.
2. Israel O, Kuten A.Early detection of cancer recurrence; 18
F-FDG PET/CT can make a difference in diagnosis and patient care.J Nucl Med2007;48:28S–35S.
3. De Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe RF, Frielink C, Verhagen AF, et al..Biological correlates of FDG uptake in non-small cell lung cancer.Lung Cancer2007;55:79–87.
4. Tian M, Zhang H, Nakasone Y, Mogi K, Endo K.Expression of Glut-1
and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study.Eur J Nucl Med Mol Imaging2004;31:5–12.
5. Gerdes J, Schwab U, Lemke H, Stein H.Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.Int J Cancer1983;31:13–20.
6. Scholzen T, Gerdes J.The Ki-67
protein; from the known and the unknown.J Cell Physiol2000;182:311–322.
7. Indinnimeo M, Cicchini C, Stazi A, Limiti MR, Ghini C, Mingazzini P, Vecchione A.Immunohistochmical assessment of Ki-67
as prognostic cellular proliferation marker in anal canal carcinoma.J Exp Clin Cancer Res2000;19:471–475.
8. Dooms C, van Baardwijk A, Verbeken E, van Suylen RJ, Stroobants S, De Ruysscher D, et al..Association between 18
F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early stage non-small cell lung cancer.J Thorac Oncol2009;4:822–828.
9. Folpe AL, Lyles RH, Sprouse JT, Conrad EU 3rd, Eary JF.(F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma.Clin Cancer Res2000;6:1279–1287.
10. Buck AC, Schirrmeister HH, Guhlmann CA, Diederichs CG, Shen C, Buchmann I, et al..Ki-67
immunostaining in pancreatic cancer and chronic active pancreatitis; does in vivo FDG uptake correlate with proliferative activity?J Nucl Med2001;42:721–725.
11. Yamamoto Y, Kameyama R, Izuishi K, Takebayashi R, Hagiike M, Asakura M, et al..Detection of colorectal cancer using 18
F-FLT PET: comparison with 18
F-FDG PET.Nucl Med Commun2009;30:841–845.
12. Deron P, Vangestel C, Goethals I, De Potter A, Peeters M, Vermeersch H, et al..FDG uptake in primary squamous cell carcinoma of the head and neck. The relationship between overexpression of glucose transporters and hexokinases, tumor proliferation and apoptosis.Nuklearmedizin2011;50:15–21.
13. Sobin LH, Wittekind Ch.TNM classification of malignant tumors2002:6th ed..Baltimore, MD:Wiley-Liss;52–103.
14. Van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al..The maximum uptake of 18
F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor -1α and GLUT-1
in non-small cell lung cancer.Eur J Cancer2007;43:1392–1398.
15. Nguyen XC, So Y, Chung JH, Lee WW, Park SY, Kim SE.High correlations between primary tumors and loco-regional metastatic lymph nodes in non-small cell lung cancer with respect to glucose transporter type 1-mediated 2-deoxy-2F18-fluoro-D-glucose uptake.Eur J Cancer2008;44:692–698.
16. Al-Sarraf N, Gately K, Lucey J, Aziz R, Doddakula K, Wilson L, et al..Clinical implication and prognostic significance of standardized uptake value of primary non-small cell lung cancer on positron emission tomography; analysis of 176 cases.Eur J Cadiothorac Surg2008;34:892–897.
17. Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, Jordan CD, et al..Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67
proliferation index.J Thorac Oncol2008;3:971–978.
18. Suzawa N, Ito M, Qiao S, Uchida K, Takao M, Yamada T, et al..Assessment of factors influencing FDG uptake in non-small cell lung cancer on PET/CT by investigating histological differences in expression of glucose transporters 1 and 3 and tumor size.Lung Cancer2011;72:191–198.
19. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl R.Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer.J Nucl Med1999;40:556–565.
20. Hiyoshi Y, Watanabe M, Imamura Y, Nagai Y, Baba Y, Yoshida N, et al..The relationship between the glucose transporter type 1 expression and 18
F-fluorodeoxyglucose uptake in esophageal squamous carcinoma.Oncology2009;76:286–292.
21. Westerterp M, Sloof GW, Hoekstra OS, ten Kate FJW, Meijer GA, Reitsma JB, et al..18
FDG uptake in oesophageal adenocarcinoma; linking biology and outcome.J Cancer Res Clin Oncol2008;134:227–236.
22. Nakajo M, Nakajo M, Tani A, Kajiya Y, Shimaoka S, Matsuda A, et al..Clinical significance of primary lesion FDG uptake for choice between oesophagectomy and endoscopic submucosal dissection for resectable oesophageal squamous cell carcinomas.Eur J Radiol2011;21:2396–2407.
23. Van Westreenen HL, Cobben DC, Jagar PL, van Dullemen HM, Wesseling J, Elsinga PH, et al..Comparison of 18
F-FLT and 18
F-FDG PET in esophageal cancer.J Nucl Med2005;46:400–404.
24. Choi JY, Jang KT, Shim YM, Kim K, Ahn G, Lee KH, et al..Prognostic significance of vascular endothelial growth factor expression and microvessel density in esophageal squamous cell carcinoma; comparison with positron emission tomography.Ann Surg Oncol2006;13:1054–1062.
25. Kato H, Takita J, Miyazaki T, Nakajima M, Fukai Y, Matsuda N, et al..Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (GLUT-1
) expression in esophageal squamous cell carcinoma.Anticancer Res2003;23:3263–3272.
26. Grabellus F, Nagarajah J, Bockisch A, KurtWerner S, Sheu SY.Glucose transporter 1 expression, tumor proliferation and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.Clin Nucl Med2012;37:121–127.
27. Kim IJ, Kim SS, Kim SJ, Lee CH, Kim YK.Relationship between biological marker expression and fluorine-18fluorodeoxyglucose uptake in incidentally detected thyroid cancer.Cancer Biother Radiopharm2010;25:309–315.
28. Kim YW, Do IG, Park YK.Expression of the GLUT 1 glucose transporter, p63 and p53 in thyroid carcinoma.Pathol Res Pract2006;202:759–765.
29. Jeong HS, Chung M, Baek CH, Ko YH, Choi JY, Son YI.Can [18
F]-fluorodeoxyglucose standardized uptake values of PET imaging predict pathologic extrathyroid invasion of thyroid papillary microcarcinoma?Laryngoscope2006;116:2133–2137.
30. Ito Y, Miyauchi A, Kakudo K, Hirokawa M, Kobayashi K, Miya A.Prognostic significance of Ki-67
labeling index in papillary thyroid carcinoma.World J Surg2010;34:3015–3021.
31. Ito Y, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, et al..Papillary microcarcinomas of the thyroid with preoperatively detectable lymph node metastasis show significantly higher aggressive characteristics on immunohistochemical examination.Oncology2005;68:87–96.
32. Mussig K, Wehrmann T, Dittmann H, Wehrmann M, Ueberberg B, Schulz S, et al..Expression of the proliferation marker Ki-67
associates with tumor staging and clinical outcome in differentiated thyroid carcinomas.Clin Endocrinol2012;77:139–145.
33. Bynn BH, Jeong UG, Hong SP, Min JJ, Chong A, Song HC, et al..Prediction of central lymph node metastasis from papillary microcarcinoma by 18
F-fluorodeoxyglucose PET/CT and ultrasonography.Ann Nucl Med2012;26:471–477.
34. Yun M, Noh TW, Cho A, Choi YJ, Hong SW, Park CS, et al..Visually discernible [18
F] fluorodeoxyglucose uptake in papillary thyroid microcarcinoma; a new potential new risk factor.J Clin Endocrinol Metab2010;95:3182–3188.
35. Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, et al..Biologic correlation of 2-[18
F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors.J Clin Oncol2010;28:3746–3753.
36. Graves EE, Maity A, Le QT.The tumor microenvironment in non-small cell lung cancer.Semin Radiat Oncol2010;20:156–163.